ISSN 0564-3783  

Main page
Information to authors
Editorial board
Mobile version

In Ukrainian

Export citations

Double punh: hepatitis C in patients with genetic defects of iron metabolism

Danilenko N.G., Siniauskaya M.G., Lukashyk S.P., Karpov I.A., Davydenko O.G.


SUMMARY. The review deals with peculiarities of chronic virus hepatitis C in patients with mutations in HFE gene, which lead to impaired iron metabolism. We discuss the sensitivity of patients having HFE mutations to: virus C invasion; progress of hepatic pathological processes during chronic hepatitis C, including the most severe complications liver cirrhosis and hepatocellular carcinoma; HCV therapy.

Key words: HFE mutations, hepatitis C virus, chronic virus infection, iron overload

Tsitologiya i Genetika 2019, vol. 53, no. 5, pp. 75-89

E-mail: cytoplasmic, svetlanalukashik

Danilenko N.G., Siniauskaya M.G., Lukashyk S.P., Karpov I.A., Davydenko O.G. Double punh: hepatitis C in patients with genetic defects of iron metabolism, Tsitol Genet., 2019, vol. 53, no. 5, pp. 75-89.

In "Cytology and Genetics":
N. G. Danilenko, M. G. Siniauskaya, S. P. Lukashyk, I. A. Karpov, O. G. Davydenko Double Punch: Hepatitis C in Patients with Genetic Defects of Iron Metabolism, Cytol Genet., 2019, vol. 53, no. 5, pp. 407417
DOI: 10.3103/S0095452719050062


1. Price, L. and Kowdley, K.V., The role of iron in the pathophysiology and treatment of chronic hepatitis C, Can. J. Gastroenterol., 2009, vol. 23, no. 12, pp. 822828.

2. Tai, A.W., Benita, Y., Peng, L.F., Kim, S.-S., Sakamoto, N., Xavier, R.J., and Chung, R.T., A functional genomic screen identifies cellular cofactors of hepatitis C virus replication, Cell Host. Microbe, 2009, vol. 5, no. 3, pp. 298307.

3. Petruzziello, A., Marigliano, S., Loquercio, G., and Cacciapuoti, C., Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes, World J. Gastroenterol., 2016, vol. 22, no. 34, pp. 78247840.

4. Eisenbach, C., Gehrke, S.G., and Stremmel, W., Iron, the HFE gene, and hepatitis C, Clin. Liver. Dis., 2004, vol. 8, no. 4, pp. 775785.

5. Wallace, D.F. and Subramaniam, V.N., Co-factors in liver disease: the role of HFE-related hereditary hemochromatosis and iron. Biochim. Biophys. Acta, 2009, vol. 1790, no. 7, pp. 66370.

6. Houghton, M., The long and winding road leading to the identification of the hepatitis C virus, J. Hepatol., 2009, vol. 51, no. 5, pp. 939948.

7. McGivern, D.R. and Lemon, S.M., Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer, Oncogene, 2011, vol. 30, no. 17, pp. 19691983.

8. Feder, J.N., Gnirke, A., Thomas, W., Tsuchihashi, Z., Ruddy, D.A., Basava, A., Dormishian, F., Domingo, R., Jr., Ellis, M.C., Fullan, A., Hinton, L.M., Jones, N.L., Kimmel, B.E., Kronmal, G.S., Lauer, P., Lee, V.K., Loeb, D.B., Mapa, F.A., McClelland, E., Meyer, N.C., Mintier, G.A., Moeller, N., Moore, T., Morikang, E., Prass, C.E., Quintana, L., Starnes, S.M., Schatzman, R.C., Brunke, K.J., Drayna, D.T., Risch, N.J., Bacon, B.R., and Wolff, R.K., A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis, Nat. Genet., 1996, vol. 13, no. 4, pp. 399408.

9. Waheed, A., Parkkila, S., Saarnio, J., Fleming, R.E., Zhou, X.Y., Tomatsu, S., Britton, R.S., Bacon, B.R., and Sly, W.S., Association of HFE protein with transferrin receptor in crypt enterocytes of human duodenum, Proc. Natl. Acad. Sci. U. S. A., 1999, vol. 96, no. 4, pp. 15791584.

10. Trinder, D., Olynyk, J.K., Sly, W.S., and Morgan, E.H., Iron uptake from plasma transferrin by the duodenum is impaired in the HFE knockout mouse, Proc. Natl. Acad. Sci. U. S. A., 2002, vol. 99, no. 8, pp. 56225626.

11. Umbreit, J., Iron deficiency: a concise review, Am. J. Hematol., 2005, vol. 78, no. 3, pp. 225231.

12. Drakesmith, H. and Prentice, A., Viral infection and iron metabolism, Nat. Rev. Microbiol., 2008, vol. 6, no. 7, pp. 541552.

13. Martinelli, A.L., Ramalho, L.N., and Zucoloto, S., Hepatic stellate cells in hepatitis C patients: relationship with liver iron deposits and severity of liver disease, J. Gastroenterol Hepatol., 2004, vol. 19, no. 1, pp. 9198.

14. Merryweather-Clarke, A.T., Pointon, J.J., Jouanolle, A.M., Rochette, J., and Robson, K.J., Geography of HFE C282Y and H63D mutations, Genet. Test., 2000, vol. 4, no. 2, pp. 183198.

15. Vujic, M., Molecular basis of HFE-hemochromatosis, Front. Pharmacol., 2014, vol. 5, no. 42, pp. 16.

16. Andrews, N.C., Hereditary hemochromatosis protein, HFE, interaction with transferring receptor, p. 2. Hereditary hemochromatosis protein, HFE, interaction with transferring receptor 2 suggests a molecular mechanism for mammalian iron sensing, J. Biol. Chem., 2006, vol. 281, no. 39, pp. 2849428498.

17. Kiss, J., Herrmann, T., Galy, B., Martinache, S., Stolte, J., Grone, H.J., Stremmel, W., Hentze, M.W., and Muckenthaler, M.U., HFE acts in hepatocytes to prevent hemochromatosis, Cell Metab., 2008, vol. 7, no. 2, pp. 173178.

18. Babitt, J.L. and Herbert, Y.L., The molecular pathogenesis of hereditary hemochromatosis seminars in liver disease, Semin. Liver. Dis., vol. 31, no. 3, pp. 280292.

19. Valore, E.V. and Ganz, T., Posttranslational processing of hepcidin in human hepatocytes is mediated by the prohormone convertase furin, Blood Cells Mol. Dis., 2008, vol. 40, no. 1, pp. 132138.

20. Park, C.H., Valore, E.V., Waring, A.J., and Ganz, T., Hepcidin, a urinary antimicrobial peptide synthesized in the liver, J. Biol. Chem., 2001, vol. 276, no. 11, pp. 78067810.

21. Ganz, T., Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation, Blood, 2003, vol. 102, no. 3, pp. 783788.

22. Nemeth, E., Tuttle, M.S., Powelson, J., Vaughn, M.B., Donovan, A., Ward, D.M., Ganz, T., and Kaplan, J., Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization, Science, 2004, vol. 306, no. 5704, pp. 20902093.

23. Hentze, M.W., Muckenthaler, M.U., Galy, B., and Camaschella, C., Two to tango: Regulation of mammalian iron metabolism, Cell, 2010, vol. 142, no. 1, pp. 2438.

24. Silva, B. and Faustino, P., An overview of molecular basis of iron metabolism regulation and the associated pathologies, Biochim. Biophys. Acta, 2015, vol. 1852, no. 7, pp. 13471359.

25. Sivitskaya, L.N. and Kushniarevich, A.I., Hereditary haemochromatosis: C282Y and H63D mutations frequencies of HFE gene in Belarus population, Proc. Natl. Acad. Sci. Belarus, 2007, vol. 6, no. 1, pp. 414418.

26. Di Bisceglie, A.M., Axiotis, C.A., Hoofnagle, J.H., and Bacon, B.R., Measurements of iron status in patients with chronic hepatitis, Gastroenterology, 1992, vol. 102, no. 6, pp. 21082113.

27. Piperno, A., DAlba R., Fargion S., Sampietro M., Parma S., Arosio V., Fare M., and Fiorelli, G., Liver iron concentration in chronic viral hepatitis: a study of 98 patients, Eur. J. Gastroenterol. Hepatol., 1995, vol. 7, no. 12, pp. 12031208.

28. Tung, B.Y., Emond, M.J., Bronner, M.P., Raaka, S.D., Cotler, S.J., and Kowdley, K.V., Hepatitis C, iron status, and disease severity: relationship with HFE mutations, Gastroenterology, 2003, vol. 124, no. 2, pp. 318326.

29. Souza, R.F., Feakins, R., and Mears, L., Relationship between serum ferritin, hepatic iron staining, diabetes mellitus and fibrosis progression in patients with chronic hepatitis C, Aliment. Pharmacol. Ther., 2005, vol. 21, no. 5, pp. 519524.

30. Silva, I.S., Perez, R.M., Oliveira, P.V., Cantagalo, M.I., Dantas, E., Sisti, C., Figueiredo-Mendes, C., Lanzoni, V.P., Silva, A., and Ferraz, M.L., Iron overload in patients with chronic hepatitis C virus infection: clinical and histological study, J. Gastroenterol. Hepatol., 2005, vol. 20, no. 2, pp. 243248.

31. Isomura, T., Yano, M., Hayashi, H., and Sakamoto, N., Excess iron in the liver of patients with chronic hepatitis C, J. Clin. Electron. Microsc., 1992, vol. 25, pp. 231237.

32. Fujita, N. and Takei, Y., Iron, hepatitis C virus, and hepatocellular carcinoma: iron reduction preaches the gospel for chronic hepatitis C, J. Gastroenterol., 2007, vol. 42, no. 10, pp. 923926.

33. Bassett, S.E., Di Bisceglie, A.M., Bacon, B.R., Sharp, R.M., Govindarajan, S., Hubbard, G.B., Brasky, K.M., and Lanford, R.E., Effects of iron loading on pathogenicity in hepatitis C virus-infected chimpanzees, Hepatology, 1999, vol. 29, no. 6, pp. 18841892.

34. Bonkovsky, H.L., Naishadham, D., Lambrecht, R.W., Chung, R.T., Hoefs, J.C., Nash, S.R., Rogers, T.E., Banner, B.F., Sterling, R.K., Donovan, J.A., Fontana, R.J., Di Bisceglie, A.M., Ghany, M.G., and Morishima, C., HALT-C Trial Group. Roles of Iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C, Gastroenterology, 2006, vol. 131, no. 5, pp. 14401451.

35. Pietrangelo, A., Hemochromatosis gene modifies course of hepatitis C viral infection, Gastroenterology, 2003, vol. 124, no. 5, pp. 15091523.

36. Pietrangelo, A., Dierssen, U., Valli, L., Garuti, C., Rump, A., Corradini, E., Ernst, M., Klein, C., and Trautwein, C., STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo, Gastroenterology, 2007, vol. 132, no. 1, pp. 294300.

37. Foka, P., Dimitriadis, A., Karamichalia, D.A., Kyratzopoulou, E., Giannimaras, D., Koskinas, J., Varaklioti, A., Mamalaki, A., and Georgopoulou, U., Alterations in the iron homeostasis network: a driving force for macrophage mediated hepatitis C virus persistency, Virulence, 2016, vol. 7, no. 6, pp. 679690.

38. Kohjima, M., Yoshimoto, T., Enjoji, M., Fukushima, N., Fukuizumi, K., Nakamura, T., Kurokawa, M., Fujimori, N., Sasaki, Y., Shimonaka, Y., Murata, Y., Koyama, S., Kawabe, K., Haraguchi, K., Sumida, Y., Harada, N., Kato, M., Kotoh, K., and Nakamuta, M., Hepcidin/ferroportin expression levels involve efficacy of pegylated-interferon plus ribavirin in hepatitis C virus-infected liver, World. J. Gastroenterol., 2015, vol. 21, no. 11, pp. 32913299.

39. Liu, H., Trinh, T.L., Dong, H., Keith, R., Nelson, D., and Liu, C., Iron regulator hepcidin exhibits antiviral activity against hepatitis C virus, PLoS One, 2012, vol. 7, no. 10. e46631.

40. Miura, K., Taura, K., Kodama, Y., Schnabl, B., and Brenner, D.A., Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity, Hepatology, 2008, vol. 48, no. 5, pp. 14201429.

41. Pirisi, M., Scott, C.A., Avellini, C., Toniutto, P., Fabris, C., Soardo, G., Beltrami, C.A., and Bartoli, E., Iron deposition and progression of disease in chronic hepatitis C. Role of interface hepatitis, portal inflammation, and HFE missense mutations, Am. J. Clin. Pathol., 2000, vol. 113, no. 4, pp. 546554.

42. Geier, A., Reugels, M., Weiskirchen, R., Wasmuth, H.E., Dietrich, C.G., Siewert, E., Gartung, C., Lorenzen, J., Bosserhoff, A.K., Brugmann, M., Gressner, A.M., Matern, S., and Lammert, F., Common heterozygous hemochromatosis gene mutations are risk factors for inflammation and fibrosis in chronic hepatitis C, Liver Int., 2004, vol. 24, no. 4, pp. 285294.

43. Erhardt, A., Maschner-Olberg, A., Mellenthin, C., Kappert, G., Adams, O., Donner, A., Willers, R., Niederau, C., and Haussinger, D., HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis, J. Hepatol., 2003, vol. 38, no. 3, pp. 335342.

44. Mills, P.R., The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C, Gut, 2002, vol. 50, no. 2, pp. 248252.

45. Lebray, P., Zylberberg, H., Hue, S., Poulet, B., Carnot, F., Martin, S., Chretien, Y., Pol., S., Caillat-Zuckman, S., Brechot, C., and Nalpas, B., Influence of HFE gene polymorphism on the progression and treatment of chronic hepatitis C, J. Viral. Hepatitis, 2004, vol. 11, no. 2, pp. 175182.

46. Gattoni, A., Parlato, A., Vangieri, B., Bresciani, M., Derna, R., and Baldassarre, R., Role of hemochromatosis genes in chronic hepatitis C, Clinica Terapeutica, 2006, vol. 157, no. 1, pp. 6168.

47. Piperno, A., Vergani, A., Malosio, I., Parma, L., Fossati, L., Ricci, A., Bovo, G., Boari, G., and Mancia, G., Hepatic iron overload in patients with chronic viral hepatitis: role of HFE gene mutations, Hepatology, 1998, vol. 28, no. 4, pp. 11051109.

48. Smith, B.C., Gorve, J., Guzail, M.A., Day, C.P., Daly, A.K., Burt, A.D., and Bassendine, M.F., Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C, Hepatology, 1998, vol. 27, no. 6, pp. 16951699.

49. Martinelli, A.L., Franco, R.F., Villanova, M.G., Figueiredo, J.F., Secaf, M., Tavella, M.H., Ramalho, L.N., Zucoloto, S., and Zago, M.A., Are haemochromatosis mutations related to the severity of liver disease in hepatitis C virus infection?, Acta Haematol., 2000, vol. 102, no. 3, pp. 152156.

50. Bonkovsky, H.L., Troy, N., McNeal, K., Banner, B.F., Sharma, A., Obando, J., Mehta, S., Koff, R.S., Liu, Q., and Hsieh, C.C., Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C, J. Hepatol., 2002, vol. 37, no. 6, pp. 848854.

51. Hezode, C., Cazeneuve, C., Coue, O., Roudot-Thoraval, F., Lonjon, I., Bastie, A., Duvoux, C., Pawlotsky, J.M., Zafrani, E.S., Amselem, S., and Dhumeaux, D., Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions. J. Hepatol., 1999, vol. 31, no. 6, pp. 97984.

52. Negro, F., Samii, K., Rubbia-Brandt, L., Quadri, R., Male, P.J., Zarski, J.P., Baud, M., Giostra, E., Beris, P., and Hadengue, A., Hemochromatosis gene mutations in chronic hepatitis C patients with and without liver siderosis, J. Med. Virol., 2000, vol. 60, no. 1, pp. 2127.

53. Bataller, R., North, K.E., and Brenner, D.A., Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal, Hepatology, 2003, vol. 37, no. 3, pp. 493503.

54. Richardson, M.M., Powell, E.E., Barrie, H.D., Clouston, A.D., Purdie, D.M., and Jonsson, J.R., A combination of genetic polymorphisms increases the risk of progressive disease in chronic hepatitis C, J. Med. Genet., 2005, vol. 42. e45.

55. Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S.Y., Alvarado, M., Anderson, H.R., Anderson, L.M., Andrews, K.G., Atkinson, C., Baddo, L.M., Barker-Collo, S., Bartels, D.H., Bell, M.L., Benjamin, E.J., Bennett, D., Bhalla, K., Bikbov, B., Bin Abdulhak, A., Birbeck, G., Blyth, F., Bolliger, I., Boufous, S., Bucello, C., Burch, M., Burney, P., Carapetis, J., Chen, H., Chou, D., Chugh, S.S., Coffeng, L.E., Colan, S.D., Colquhoun, S., Colson, K.E., Condon, J., Connor, M.D., Cooper, L.T., Corriere, M., Cortinovis, M., de Vaccaro, K.C., Couser, W., Cowie, B.C., Criqui, M.H., Cross, M., Dabhadkar, K.C., Dahodwala, N., De Leo, D., Degenhardt, L., Delossantos, A., Denenberg, J., Des Jarlais, D.C., Dharmaratne, S.D., Dorsey, E.R., Driscoll, T., Duber, H., Ebel, B., Erwin, P.J., Espindola, P., Ezzati, M., Feigin, V., Flaxman, A.D., Forouzanfar, M.H., Fowkes, F.G., Franklin, R., Fransen, M., Freeman, M.K., Gabriel, S.E., Gakidou, E., Gaspari, F., Gillum, R.F., Gonzalez-Medina, D., Halasa, Y.A., Haring, D., Harrison, J.E., Havmoeller, R., Hay, R.J., Hoen, B., Hotez, P.J., Hoy, D., Jacobsen, K.H., James, S.L., Jasrasaria, R., Jayaraman, S., Johns, N., Karthikeyan, G., Kassebaum, N., Keren, A., Khoo, J.P., Knowlton, L.M., Kobusingye, O., Koranteng, A., Krishnamurthi, R., Lipnick, M., Lipshultz, S.E., Ohno, S.L., Mabweijano, J., MacIntyre, M.F., Mallinger, L., March, L., Marks, G.B., Marks, R., Matsumori, A., Matzopoulos, R., Mayosi, B.M., McAnulty, J.H., McDermott, M.M., McGrath, J., Mensah, G.A., Merriman, T.R., Michaud, C., Miller, M., Miller, T.R., Mock, C., Mocumbi, A.O., Mokdad, A.A., Moran, A., Mulholland, K., Nair, M.N., Naldi, L., Narayan, K.M., Nasseri, K., Norman, P., ODonnell, M., Omer, S.B., Ortblad, K., Osborne, R., Ozgediz, D., Pahari, B., Pandian, J.D., Rivero, A.P., Padilla, R.P., Perez-Ruiz, F., Perico, N., Phillips, D., Pierce, K., Pope, C.A., Porrini, E., Pourmalek, F., Raju, M., Ranganathan, D., Rehm, J.T., Rein, D.B., Remuzzi, G., Rivara, F.P., Roberts, T., De Leon, F.R., Rosenfeld, L.C., Rushton, L., Sacco, R.L., Salomon, J.A., Sampson, U., Sanman, E., Schwebel, D.C., Segui-Gomez, M., Shepard, D.S., Singh, D., Singleton, J., Sliwa, K., Smith, E., Steer, A., Taylor, J.A., Thomas, B., Tleyjeh, I.M., Towbin, J.A., Truelsen, T., Undurraga, E.A., Venketasubramanian, N., Vijayakumar, L., Vos, T., Wagner, G.R., Wang, M., Wang, W., Watt, K., Weinstock, M.A., Weintraub, R., Wilkinson, J.D., Woolf, A.D., Wulf, S., Yeh, P.H., Yip, P., Zabetian, A., Zheng, Z.J., Lopez, A.D., Murray, C.J., AlMazroa, M.A., and Memish, Z.A. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010, Lancet, 2012, vol. 380, no. 9859, pp. 20952128.

56. Bruix, J. and Sherman, M., Management of hepatocellular carcinoma: an update, Hepatology, 2011, vol. 53, no. 3, pp. 10201022.

57. King, L.Y., Canasto Chibuque, C., Johnson, K.B., Yip, S., Chen, X., Kojima, K., Deshmukh, M., Venkatesh, A., Tan, P.S., Sun, X., Villanueva, A., Sangiovanni, A., Nair, V., Mahajan, M., Kobayashi, M., Kumada, H., Iavarone, M., Colombo, M., Fiel, M.I., Friedman, S.L., Llovet, J.M., Chung, R.T., and Hoshida, Y.A., Genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration, Gut, 2015, vol. 64, no. 8, pp. 12961302.

58. Bonkovsky, H.L., Jawaid, Q., Tortorelli, K., LeClair, P., Cobb, J., Lambrecht, R.W., and Banner, B.F., Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in nonalcoholic steatohepatitis, J. Hepatol., 1999, vol. 31, no. 3, pp. 421429.

59. Moczulski, D.K., Grzeszczak, W., and Gawlik, B., Role of hemochromatosis C282Y and H63D mutations in HFE gene in development of type 2 diabetes and diabetic nephropathy, Diabetes Care, 2001, vol. 24, no. 7, pp. 11871191.

60. Melis, M.A., Cau, M., Deidda, F., Barella, S., Cao, A., and Galanello, R., H63D mutation in the HFE gene increases iron overload in beta-thalassemia carriers, Haematologica, 2002, vol. 87, no. 3, pp. 242245.

61. Tannapfel, A., Stolzel, U., Kostler, E., Melz, S., Richter, M., Keim, V., Schuppan, D., and Wittekind, C., C282Y and H63D mutation of the hemochromatosis gene in German porphyria cutanea tarda patients, Virchows Arch., 2001, vol. 439, no. 1, pp. 15.

62. Lee, D.W., Andersen, J.K., and Kaur, D., Iron dysregulation and neurodegeneration: the molecular connection, Mol. Interv., 2006, vol. 6, no. 2, pp. 8997.

63. Xia, J., Xu, H., Jiang, H., and Xie, J., The association between the C282Y and H63D polymorphisms of HFE gene and the risk of Parkinsons disease: a meta-analysis, Neurosci. Lett., 2015, vol. 595, pp. 99103.

64. Lian, J., Xu, L., and Huang, Y., Le Y., Jiang D., Yang X., Xu W., Huang X., Dong C., Ye M., Zhou J., Duan S., Meta-analyses of HFE variants in coronary heart disease, Gene, 2013, vol. 527, no. 1, pp. 167173.

65. Ellervik, C., Tybjaerg-Hansen, A., and Appleyard, M., Hereditary hemochromatosis genotypes and risk of ischemic stroke, Neurology, 2007, vol. 68, no. 13, pp. 10251031.

66. Sini, M., Sorbello, O., Civolani, A., and Demelia, L., Hemochromatosis gene mutations: prevalence and effects on pegylated-interferon and ribavirin therapy response in chronic hepatitis C in Sardinia, J. Clin. Exp. Hepatol., 2012, vol. 2, no. 3, pp. 211217.

67. Mazzanti, R., Arena, U., and Tassi, R., Hepatocellular carcinoma: where are we?, World J. Exp. Med., 2016, vol. 6, no. 1, pp. 2136.

68. Della, CorteC., Aghemo, A., and Colombo, M., Individualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategies, World J. Gastroenterol., 2013, vol. 19, no. 9, pp. 13591371.

69. World Health Organization. Mortality database.

70. Bruno, S., Crosignani, A., Maisonneuve, P., Rossi, S., Silini, E., and Mondelli, M.U., Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study, Hepatology, 2007, vol. 46, no. 5, pp. 13506.

71. Lauret, E., Rodriguez, M., Gonzalez, S., Lina-res, A., Lopez-Vazquez, A., Martinez-Borra, J., Rodrigo, L., and Lopez-Larrea, C., HFE gene mutations in alcoholic and virus related cirrhotic patients with hepatocellular carcinoma, Am. J. Gastroenterol., 2002, vol. 97, no. 4, pp. 101610121.

72. Jin, F., Qu Li-Shuai, Shen X.Z., Association between C282Y and H63Dmutations of the HFE gene with hepatocellular carcinoma in European populations: a meta-analysis, J. Exp. Clin. Cancer Res., 2010, vol. 29, no. 1, p. 18.

73. Nahon, P., Sutton, A., Rufat, P., Simon, C., Trinchet, J.C., Gattegno, L., Beaugrand, M., and Charnaux, N., Chemokine system polymorphisms, survival and hepatocellular carcinoma occurrence in patients with hepatitis C virus-related cirrhosis, World J. Gastroenterol., 2008, vol. 14, no. 5, pp. 713719.

74. Kew, M.C., Hepatic iron overload and hepatocellular carcinoma, Cancer Lett., 2009, vol. 286, no. 1, pp. 3843.

75. Marshall, A., Lukk, M., Kutter, C., Davies, S., Alexander, G., and Odom, D.T., Global gene expression profiling reveals Spink1 as a potential hepatocellular carcinoma marker, PLoS One, 2013, vol. 8, no. 3, e59459.

76. Jiang, S., Yang, Z., Li, W., Li, X., Wang, Y., Zhang, J., Xu, C., Chen, P.J., Hou, J., McCrae, M.A., Chen, X., Zhuang, H., and Lu, F., Re-evaluation of the carcinogenic significance of hepatitis B virus integration in hepatocarcinogenesis, PLoS One, 2012, vol. 7, no. 9, e40363.

77. Cevik, O., Li, D., Baljinnyam, E., Manvar, D., Pimenta, E.M., Waris, G., Barnes, B.J., and Kaushik-Basu, N., Interferon regulatory factor 5 (IRF5) suppresses hepatitis C virus (HCV) replication and HCV-associated hepatocellular carcinoma, J. Biol. Chem., 2017, vol. 292, no. 52, pp. 2167621689.

78. Furutani, T., Hino, K., Okuda, M., Gondo, T., Nishina, S., Kitase, A., Korenaga, M., Xiao, S.Y., Weinman, S.A., Lemon, S.M., Sakaida, I., and Okita, K., Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein, Gastroenterology, 2006, vol. 130, no. 7, pp. 20872098.

79. Hoshida, Y., Fuchs, B.C., Bardeesy, N., Baumert, T.F., and Chung, R.T., Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma, J. Hepatol., 2014, vol. 61, no. 10, pp. S79S90.

80. Singal, A.G., Manjunath, H., Yopp, A.C., Beg, M.S., Marrero, J.A., Gopal, P., and Waljee, A.K., The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis, Am. J. Gastroenterol., 2014, vol. 109, no. 3, pp. 325334.

81. El-Serag, H.B., Kanwal, F., Davila, J.A., Kramer, J., and Richardson, P., A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis, Gastroenterology, 2014, vol. 46, no. 5, pp. 12491255.

82. McHutchison, J.G., Gordon, S.C., Schiff, E.R., Shiffman, M.L., Lee, W.M., Rustgi, V.K., Goodman, Z.D., Ling, M.H., Cort, S., and Albrecht, J.K., Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C, N. Engl. J. Med., 1998, vol. 339, no. 21, pp. 14851492.

83. Glue, P., Rouzier-Panis, R., Raffanel, C., Sabo, R., Gupta, S.K., Salfi, M., Jacobs, S., and Clement, R.P., A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C, Hepatology, 2000, vol. 32, no. 3, pp. 647653.

84. Manns, M.P., John, G., McHutchison, RustgiV.K., Shiffman, M., Reindollar, R., Goodman, Z.D., Koury, K., Ling, M., and Albrecht, J.K., Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial, Lancet, 2001, vol. 358, no. 9286, pp. 958965.

85. Katano, Y., Honda, T., Hayashi, K., Ishigami, M., Itoh, A., Hirooka, Y., Nakano, I., and Goto, H., Clinical impact of HFE mutations in Japanese patients with chronic hepatitis C, J. Gastroenterol. Hepatol., 2012, vol. 27, no. 6, pp. 11121116.

86. Carvalho, I., Cardoso, C., Cordeiro, J.V., Azevedo, J.E., Neefjes, J., and de Sousa, M., HFE cross-talks with the MHC class I antigen presentation pathway, Blood, 2005, vol. 106, pp. 971977.

87. Lawless, M., White, M., Mankan, A., ODwyer, M.J., and Norris, S., Elevated MCP-1 serum levels are associated with the H63D mutation and not the C282Y mutation in hereditary hemochromatosis, Tissue Antigens, 2007, vol. 70, no. 4, pp. 294300.

88. Li, S.H., Zhao, H., Ren, Y.Y., Liu, Y.Z., Song, G., Ding, P., Ding, Y.P., and Wang, G.Q., The H63D mutation of the hemochromatosis gene is associated with sustained virological response in chronic hepatitis C patients treated with interferon-based therapy: a meta-analysis, Tohoku J. Exp. Med., 2012, vol. 226, no. 4, pp. 293299.

89. Kato, J., Miyanishi, K., Kobune, M., Nakamura, T., Takada, K., Takimoto, R., Kawano, Y., Takahashi, S., Takahashi, M., Sato, Y., Takayama, T., and Niitsu, Y., Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C, J. Gastroenterol., 2007, vol. 42, no. 10, pp. 830836.

90. Desai, T.K., Jamil, L.H., Balasubramaniam, M., Koff, R., and Bonkovsky, H.L., Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: a meta-analysis of six prospective randomized controlled trials, Dig. Dis. Sci., 2008, vol. 53, no. 3, pp. 815822.

91. Nirei, K., Matsuoka, S., Nakamura, H., Matsumura, H., and Moriyama, M., Incidence of hepatocellular carcinoma reduced by phlebotomy treatment in patients with chronic hepatitis C, Intern. Med., 2015, vol. 54, no. 2, pp. 107117.

92. Kazemi-Shirazi, L., Datz, C., Maier-Dobersberger, T., Kaserer, K., Hackl, F., Polli, C., Steindl, P.E., Penner, E., and Ferenci, P., The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C, Gastroenterology, 1999, vol. 116, no. 1, pp. 127134.

93. Sampietro, M., Piperno, A., Lupica, L., Arosio, C., Vergani, A., Corbetta, N., Malosio, I., Mattioli, M., Fracanzani, A.L., Cappellini, M.D., Fiorelli, G., and Fargion, S., High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda, Hepatology, 1998, vol. 27, no. 1, pp. 181184.

94. Dostalikova-Cimburova, M., Kratka, K., and Stransky, J., Iron overload and HFE gene mutations in Czech patients with chronic liver diseases, Dis. Markers, 2012, vol. 32, no. 1, pp. 6572.

Copyright© ICBGE 2002-2020 Coded & Designed by Volodymyr Duplij Modified 26.11.20